Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal preserving treatment for early rectal cancer
2024-517410-15-01Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of capecitabine in rectal cancer (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Three-year local recurrence rate. Planned start Jan 2025; status: authorised.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-517410-15-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517410-15-01.